(Q36483161)

English

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Daniel Keizman

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Maya Gottfried

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Maya Ish-Shalom

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Natalie Maimon

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Avivit Peer

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Avivit Neumann

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Eli Rosenbaum

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Svetlana Kovel

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Roberto Pili

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Victoria Sinibaldi

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Michael A Carducci

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hans Hammers

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Mario A Eisenberger

13

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Avishay Sella

14

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

12 September 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1508-1514

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

CYP17 inhibition as a hormonal strategy for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Cancer-related inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Targeting CYP17: established and novel approaches in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

30 September 2017

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Effective testosterone suppression for prostate cancer: is there a best castration therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3528383

21 September 2018

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/22971522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1634/THEONCOLOGIST.2012-0125

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36483161&oldid=1635127070"